非肌层浸润性膀胱癌灌注治疗的研究进展
Research Progress of Perfusion Therapy for Non-Muscular Invasive Bladder Cancer
DOI: 10.12677/acm.2025.1541129, PDF,   
作者: 向 涛, 罗家顺：吉首大学医学院，湖南 吉首；范诗秋：吉首大学第一附属医院泌尿外二科，湖南 吉首
关键词: 膀胱癌；灌注治疗；研究进展；癌症治疗；Bladder Cancer； Intravesical Therapy； Research Progress； Cancer Therapy
摘要: 膀胱癌是全球泌尿系统最常见的恶性肿瘤之一，在中国的发病率更是稳居第一，其中70%的膀胱癌临床分型为非肌层浸润性膀胱癌(NMIBC)，NMIBC预后良好，但其术后易复发、易侵袭的特点更是严重影响了患者的身心健康，给患者和社会带来沉重的经济负担。正因如此，术后正确的辅助治疗成为了预防及降低术后肿瘤复发及侵袭危险度的关键。本文旨在综述非肌层浸润型膀胱癌灌注治疗的现状，汇总最新的研究成果，探讨其在临床中的应用效果，以期为临床实践提供参考并推动该领域的进一步研究。
Abstract: Bladder cancer is one of the most common malignant tumors of urinary system in the world, and its incidence in China ranks the first. Among them, 70% of bladder cancer is clinically classified as non-invasive bladder cancer (NMIBC). NMIBC has a good prognosis, but its characteristics of easy recurrence and invasion after surgery seriously affect the physical and mental health of patients. It brings a heavy economic burden to patients and society. Because of this, the correct postoperative adjuvant therapy has become the key to prevent and reduce the risk of postoperative tumor recurrence and invasion. The purpose of this paper is to review the current status of perfusion therapy for non-muscular invasive bladder cancer, summarize the latest research results, and discuss its clinical application effect, in order to provide references for clinical practice and promote further research in this field.
文章引用：向涛, 罗家顺, 范诗秋. 非肌层浸润性膀胱癌灌注治疗的研究进展[J]. 临床医学进展, 2025, 15(4): 1851-1854. https://doi.org/10.12677/acm.2025.1541129

参考文献

[1] Hall, M.C., Chang, S.S., Dalbagni, G., Pruthi, R.S., Seigne, J.D., Skinner, E.C., et al. (2007) Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update. Journal of Urology, 178, 2314-2330. [Google Scholar] [CrossRef] [PubMed]
[2] 王宁, 刘硕, 杨雷, 等. 2018全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2019, 5(1): 87-97.
[3] 韩苏军, 张思维, 陈万青, 等. 中国膀胱癌发病现状及流行趋势分析[J]. 癌症进展, 2013, 11(1): 89-95.
[4] Lopez-Beltran, A., Bassi, P., Pavone-Macaluso, M. and Montironi, R. (2004) Handling and Pathology Reporting of Specimens with Carcinoma of the Urinary Bladder, Ureter, and Renal Pelvis. European Urology, 45, 257-266. [Google Scholar] [CrossRef] [PubMed]
[5] Zhang, J., Wang, Y., Weng, H., Wang, D., Han, F., Huang, Q., et al. (2019) Management of Non-Muscle-Invasive Bladder Cancer: Quality of Clinical Practice Guidelines and Variations in Recommendations. BMC Cancer, 19, Article No. 1054. [Google Scholar] [CrossRef] [PubMed]
[6] 唐多才, 周术奎, 张桂银, 等. 非肌层浸润性膀胱癌行初次经尿道膀胱肿瘤电切术的术后复发危险因素分析[J]. 中国癌症杂志, 2023, 33(5): 478-483.
[7] Morales, A., Eidinger, D. and Bruce, A.W. (2017) Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors. Journal of Urology, 197, S142-S145. [Google Scholar] [CrossRef] [PubMed]
[8] 周秋根, 姜睿. 浅表性膀胱癌的治疗现状与进展[J]. 西南军医, 2008, 10(5): 100-102.
[9] Redelman-Sidi, G., Glickman, M.S. and Bochner, B.H. (2014) The Mechanism of Action of BCG Therapy for Bladder Cancer—A Current Perspective. Nature Reviews Urology, 11, 153-162. [Google Scholar] [CrossRef] [PubMed]
[10] 司占南. 吡柔比星膀胱热灌注化疗降低高级别非肌层浸润性膀胱癌电切术后复发疗效分析[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2022.
[11] 吴海超, 陈振杰, 付什, 等. 长期与短期膀胱内灌注表柔比星预防非肌层浸润性膀胱癌复发的比较: Meta分析和系统评价[J]. 临床泌尿外科杂志, 2021, 36(10): 812-819.
[12] 方晓. 表柔比星膀胱灌注联合经尿道电切术治疗非肌层浸润性膀胱癌的疗效观察[J]. 实用中西医结合临床, 2021, 21(7): 87-88.
[13] 肖祥书. 吡柔比星膀胱灌注预防膀胱肿瘤复发的有效性和药理分析[J]. 中外医学研究, 2013, 11(4): 33-34.
[14] 孟涛, 王纪科, 刘锦波, 等. 吉西他滨与表柔比星序贯辅助治疗经尿道膀胱肿瘤切除术后非肌层浸润性膀胱癌的效果研究[J]. 中国肿瘤临床与康复, 2020, 27(6): 738-741.
[15] 李靖, 王斌, 张震, 等. 膀胱灌注流量及膀胱充盈程度在膀胱热灌注化疗中的应用[J]. 实用医学杂志, 2020, 36(15): 2167-2169.
[16] Colombo, R., Salonia, A., Leib, Z., Pavone‐Macaluso, M. and Engelstein, D. (2010) Long‐term Outcomes of a Randomized Controlled Trial Comparing Thermochemotherapy with Mitomycin‐C Alone as Adjuvant Treatment for Non‐muscle‐Invasive Bladder Cancer (NMIBC). BJU International, 107, 912-918. [Google Scholar] [CrossRef] [PubMed]
[17] 王玉呈. 浅表性膀胱肿瘤术后表柔比星热灌注化疗效果观察[D]: [硕士学位论文]. 西宁: 青海大学, 2017.
[18] Jung, J.H., Gudeloglu, A., Kiziloz, H., Kuntz, G.M., Miller, A., Konety, B.R., et al. (2017) Intravesical Electromotive Drug Administration for Non-Muscle Invasive Bladder Cancer. Cochrane Database of Systematic Reviews, No. 9, CD011864. [Google Scholar] [CrossRef] [PubMed]
[19] Di Stasi, S.M., Giannantoni, A., Giurioli, A., Valenti, M., Zampa, G., Storti, L., et al. (2006) Sequential BCG and Electromotive Mitomycin versus BCG Alone for High-Risk Superficial Bladder Cancer: A Randomised Controlled Trial. The Lancet Oncology, 7, 43-51. [Google Scholar] [CrossRef] [PubMed]

为你推荐